IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed ...

The US Food and Drug Administration may limit Covid-19 boosters shots to high-risk groups from 2025; Pfizer reviewing proposal as agency seeks new trials, clearer risk labels for younger males ...

Data support that targeting NRP1 with antisense oligonucleotides is a promising therapeutic strategy for solid cancers where ...

New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical ...

Depending on tumor location, presurgical radiation can improve overall survival, but that option comes with an increased risk ...

On January 29, 2025, Inventiva announced the publication in Journal of Hepatology of the results of the ...

Patients with stroke and a mild or moderate level of neurologic impairment can be monitored less intensively after thrombolysis with no safety issues, a new study suggests.

The United States is tightening its approval standards for COVID-19 boosters, a shift that has prompted growing concern in ...

Swiss pharma giant Novartis is diving into research on ageing to tap the growing market for drugs that help keep older adults ...

A new treatment for patients with severe nosebleeds is being rolled out at a hospital in Hull following a trial. About 60% of ...

People are being urged to help develop new medical treatments by getting involved in research at Royal United Hospitals Bath NHS Foundation Trust.

Australia's Therapeutic Goods Administration (TGA) approved a drug called donanemab for people in the early stages of Alzheimer's ...